Finally, Effective Treatments for Tardive Dyskinesia
The Carlat Hospital Psychiatry Report, Volume 1, Number 3&4, April 2021
https://www.thecarlatreport.com/newsletter-issue/chprv1n3-4/
Issue Links: Learning Objectives | Editorial Information
Topics: Adjunct treatment | AIMS test (Assessment of Involuntary Movement) | Antipsychotics | Assent | Austedo | Deutetrabenazine | Ingrezza | Tardive dyskinesia | Tetrabenazine | Valbenazine | VMAT2 Inhibitors | Xenazine
Farah Khorassani, PharmD.
Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY.
Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
VMAT-2 inhibitors significantly reduce the symptoms of tardive dyskinesia. We learn how to prescribe them and what side effects and drug interactions to watch for.
You can't view details of this content, please login or buy subscription here